Variable Interest Entities	9 Months Ended
Sep. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities As of September 30, 2025, the variable interest entities (“VIEs”) are: (i) the Affiliated Medical Groups; and (ii) the Affiliated Pharmacy. The Company determined that it is the primary beneficiary of these entities for accounting purposes because it has the ability to direct the activities that most significantly affect the entities’ economic performance and has the obligation to absorb the losses. Under the VIE model, the Company presents the results of operations, cash flows, and the financial position of the VIEs as part of the consolidated financial statements of the Company as if the consolidated group were a single economic entity. The assets of the VIEs can only be used to settle the obligations of the VIEs. There is no noncontrolling interest upon consolidation of the entities. The results of operations and cash flows of the VIEs are also included in the Company’s unaudited condensed consolidated financial statements. Apostrophe Pharmacy LLC was an Affiliated Pharmacy and a VIE through April 2025 when, as a result of a change of ownership, it became a wholly-owned subsidiary of the Company and was no longer considered an Affiliated Pharmacy or a VIE. Previously, the Company was the primary beneficiary of the entity and consolidated its operations under the VIE model. The change of ownership did not have a material impact on the Company’s unaudited condensed consolidated financial statements because it was previously fully consolidated under the VIE model and had no noncontrolling interest. As of September 30, 2025 and December 31, 2024, the Company’s unaudited condensed consolidated balance sheets included current and total assets of $92.5 million and $56.1 million, respectively, for the VIEs. As of September 30, 2025 and December 31, 2024, current and total liabilities were $9.4 million and $16.6 million, respectively. All amounts are after elimination of intercompany transactions, balances, and non-cash impact of operating leases. For the three months ended September 30, 2025 and 2024, the VIEs charged $95.4 million and $57.8 million, respectively, for services rendered. For the nine months ended September 30, 2025 and 2024, the VIEs charged $319.4 million and $129.9 million, respectively, for services rendered. For the three months ended September 30, 2025 and 2024, operations of the VIEs generated net losses of $7.0 million and $11.5 million, respectively, inclusive of administrative expenses. For the nine months ended September 30, 2025 and 2024, operations of the VIEs generated net losses of $20.5 million and $16.9 million, respectively, inclusive of administrative expenses.

As of September 30, 2025, the variable interest entities (“VIEs”) are: (i) the Affiliated Medical Groups; and (ii) the Affiliated Pharmacy. The Company determined that it is the primary beneficiary of these entities for accounting purposes because it has the ability to direct the activities that most significantly affect the entities’ economic performance and has the obligation to absorb the losses. Under the VIE model, the Company presents the results of operations, cash flows, and the financial position of the VIEs as part of the consolidated financial statements of the Company as if the consolidated group were a single economic entity. The assets of the VIEs can only be used to settle the obligations of the VIEs. There is no noncontrolling interest upon consolidation of the entities. The results of operations and cash flows of the VIEs are also included in the Company’s unaudited condensed consolidated financial statements. Apostrophe Pharmacy LLC was an Affiliated Pharmacy and a VIE through April 2025 when, as a result of a change of ownership, it became a wholly-owned subsidiary of the Company and was no longer considered an Affiliated Pharmacy or a VIE. Previously, the Company was the primary beneficiary of the entity and consolidated its operations under the VIE model. The change of ownership did not have a material impact on the Company’s unaudited condensed consolidated financial statements because it was previously fully consolidated under the VIE model and had no noncontrolling interest.

As of September 30, 2025 and December 31, 2024, the Company’s unaudited condensed consolidated balance sheets included current and total assets of $92.5 million and $56.1 million, respectively, for the VIEs. As of September 30, 2025 and December 31, 2024, current and total liabilities were $9.4 million and $16.6 million, respectively. All amounts are after elimination of intercompany transactions, balances, and non-cash impact of operating leases.

For the three months ended September 30, 2025 and 2024, the VIEs charged $95.4 million and $57.8 million, respectively, for services rendered. For the nine months ended September 30, 2025 and 2024, the VIEs charged $319.4 million and $129.9 million, respectively, for services rendered. For the three months ended September 30, 2025 and 2024, operations of the VIEs generated net losses of $7.0 million and $11.5 million, respectively, inclusive of administrative expenses. For the nine months ended September 30, 2025 and 2024, operations of the VIEs generated net losses of $20.5 million and $16.9 million, respectively, inclusive of administrative expenses.